TP53 and pancreatic neoplasm: To establish a chronic pancreatitis-associated pancreatic cancer model, we treated pancreas-specific Kras and Tp53 mutant (KrasLSL-G12D, Tp53flox/+, p48-Cretg or KPC) mice with hourly intraperitoneal injections of caerulein for 7 hours per day for two consecutive days (Supplementary Fig. 9d)64–66.